DELAVIRDINE

DELAVIRDINE Struktur
136817-59-9
CAS-Nr.
136817-59-9
Englisch Name:
DELAVIRDINE
Synonyma:
U-90152;DELAVIRDINE;Bhap-U 90152;Delavirdine D8;Unii-dol5F9jd3e;DELAVIRDINE USP/EP/BP;147221-93-0 (Mesylate);$2200/10G,$5700/50G,96% ,IN STOCK;Delavirdine & Delavirdine Mesylate;Delavirdine - U 90152 | Rescriptor
CBNumber:
CB8292151
Summenformel:
C22H28N6O3S
Molgewicht:
456.56
MOL-Datei:
136817-59-9.mol

DELAVIRDINE Eigenschaften

Schmelzpunkt:
226-228°C
Siedepunkt:
732.0±70.0 °C(Predicted)
Dichte
1.388
storage temp. 
-20°C Freezer
Löslichkeit
Chloroform (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
pKa1 4.56; pKa2 8.9(at 25℃)
Farbe
Pale Yellow
Wasserlöslichkeit
30g/L(temperature not stated)

Sicherheit

DELAVIRDINE Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Delavirdine, a bisheteroarylpiperazine derivative, is a potent nonnucleoside RT inhibitor of activity specific for HIV-1. The U.S. FDA has approved this drug for use in combination with other anti-HIV agents. In Phase I/II study trials, it demonstrated sustained improvements in CD4 cell counts, p24 antigen levels, and RNA viral load. Promising results were obtained when the drug was used in two- or three-drug combinations with nucleoside drugs. Combination of delavirdine with ddI, ddC, or ZDV demonstrated additive or synergistic effects. Delavirdine with ZDV, however, was more beneficial in early HIV infection. Combinations of nevirapine and delavirdine had an antagonistic effect on HIV-1 RT inhibition.

Chemische Eigenschaften

Crystalline Solid

Definition

ChEBI: The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor ith activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.

Indications

Delavirdine (Rescriptor) is approved for the treatment of HIV-1 infection in adults and adolescents over age 16 as part of a combination therapy. Rash accompanied by pruritus is the most frequent adverse effect of this agent; however, it usually resolves within several weeks of treatment. Severe skin reactions are rare. Headache, nausea, vomiting, diarrhea, fatigue, and elevated hepatic enzymes also may be associated with delavirdine administration.

Acquired resistance

The predominant amino acid substitution associated with resistance is at position 236 of the HIV reverse transcriptase.

Allgemeine Beschreibung

Delavirdine (Rescriptor) must be used with at least twoadditional antiretroviral agents to treat HIV-1 infections.The oral absorption of delavirdine is rapid, and peakplasma concentrations develop in 1 hour. Extensive metabolismoccurs in the liver by CYP isozyme 3A (CYP3A) orpossibly CYP2D6. Bioavailability is 85%. Unlike nevirapine,which is 48% protein bound, delavirdine is more than98% protein bound. The half-life is 2 to 11 hours, andelimination is 44% in feces, 51% in urine, and less than 5%unchanged in urine. Delavirdine induces its own metabolism.Oral dosage forms are supplied as a 200-mg capsuleand a 100-mg tablet.

Pharmazeutische Anwendungen

A complex piperazine derivative, formulated for oral administration.

Mechanism of action

Delavirdine directly inhibits RT and DNA-directed DNA polymerase activities of HIV-1 after the formation of the enzyme–substrate complexes, thereby causing chain-termination effects.

Pharmakokinetik

Oral absorption: Not known/available Cmax 400 mg oral thrice daily: c. 19.3 mg/L Cmin 400 mg oral thrice daily: c. 8.3 mg/L Plasma half-life: c. 6 h Volume of distribution: c. 0.7 L/kg Plasma protein binding: c. 98% Absorption and distribution
It is rapidly absorbed following oral administration. Food has no significant effect on absorption. It is distributed predominantly into blood plasma and CNS penetration is poor. The semen:plasma ratio is about 0.02. It is not known if it is distributed into breast milk.
Metabolism and excretion
Several metabolites are formed by the CYP3A4 isoform of cytochrome P450 and it is a potent inhibitor of this enzyme system. Around 44% of the drug is recovered in feces and 51% in urine, about 5% as unchanged drug. Given the predominant hepatic metabolism, caution should be exercised in patients with impaired hepatic function.

Clinical Use

Treatment of HIV disease in adults and children over 12 years of age (in combination with other antiretroviral agents)
Delavirdine has fallen out of favor with the increasing preference for antiretrovirals than can be dosed twice or once daily.

Nebenwirkungen

Around 18% of patients experience a diffuse, maculopapular, erythematous and often pruritic rash. Dose titration does not appear to reduce the incidence of this side effect. The rash usually first appears within 1 month of commencing therapy and resolves within 2 weeks without dose modification. In about 4% of cases it is severe enough to warrant discontinuation of treatment.

DELAVIRDINE Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


DELAVIRDINE Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 97)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Wuhan Quanjinci New Material Co.,Ltd.
+86-15271838296; +8615271838296
kyra@quanjinci.com China 1512 58
Henan Fengda Chemical Co., Ltd
+86-371-86557731 +86-13613820652
info@fdachem.com China 20287 58
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29884 58
Chongqing Chemdad Co., Ltd
+86-023-6139-8061 +86-86-13650506873
sales@chemdad.com China 39894 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49374 58
SIMAGCHEM CORP
+86-13806087780
sale@simagchem.com China 17365 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226
sales@hzclap.com CHINA 6312 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 22883 58
Dayang Chem (Hangzhou) Co.,Ltd.
571-88938639 +8617705817739
info@dycnchem.com China 52849 58
TargetMol Chemicals Inc.

support@targetmol.com United States 38632 58

136817-59-9()Verwandte Suche:


  • U-90152
  • DELAVIRDINE
  • 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine
  • 147221-93-0 (Mesylate)
  • 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
  • Bhap-U 90152
  • Unii-dol5F9jd3e
  • Delavirdine & Delavirdine Mesylate
  • 1-[3-(Isopropylamino)-2-pyridyl]-4-[(5-methanesulfonamidoindol-2-yl)carbonyl]piperazine
  • 1-[3-[(1-Methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-y1]carbonyl]piperazine
  • N-[2-[[4-[3-[(1-Methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]methanesulfonamide
  • MethanesulfonaMide, N-[2-[[4-[3-[(1-Methylethyl)aMino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]-
  • N-(2-(4-(3-(IsopropylaMino)pyridin-2-yl)piperazine-1-carbonyl)-1H-indol-5-yl)MethanesulfonaMide
  • Delavirdine D8
  • DELAVIRDINE USP/EP/BP
  • Delavirdine - U 90152 | Rescriptor
  • $2200/10G,$5700/50G,96% ,IN STOCK
  • 136817-59-9
  • C22H28N6O3S
  • Anti-virals
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Non-nucleoside Reverse Transcriptase
  • Pharmaceuticals
  • Anti-viral Compounds
  • API
Copyright 2019 © ChemicalBook. All rights reserved